Compare AMTB & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | CDNA |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.0M | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | AMTB | CDNA |
|---|---|---|
| Price | $22.73 | $19.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $23.75 | ★ $26.67 |
| AVG Volume (30 Days) | 303.6K | ★ 656.6K |
| Earning Date | 01-22-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.26 | 1.22 |
| Revenue | ★ $394,190,000.00 | $357,998,000.00 |
| Revenue This Year | $8.81 | $14.49 |
| Revenue Next Year | $7.78 | $11.32 |
| P/E Ratio | $17.81 | ★ $16.16 |
| Revenue Growth | ★ 43.98 | 14.46 |
| 52 Week Low | $15.62 | $10.96 |
| 52 Week High | $24.30 | $25.55 |
| Indicator | AMTB | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 48.29 |
| Support Level | $21.97 | $18.81 |
| Resistance Level | $23.55 | $21.00 |
| Average True Range (ATR) | 0.70 | 1.11 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 67.68 | 40.03 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.